<div id="readability-page-1"><p>Dominari (NASDAQ:DOMH - Get Free Report) is expected to issue its resultson Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $30.0760 million for the quarter.</p><h2>Dominari Trading Up 7.6%</h2><p>Shares of DOMH stock opened at $3.39 on Wednesday. The firm has a fifty day moving average price of $3.00 and a 200 day moving average price of $3.96. The company has a market cap of $76.65 million, a P/E ratio of -0.87 and a beta of 0.69. Dominari has a 12 month low of $2.68 and a 12 month high of $8.40. </p><h2>Dominari Dividend Announcement</h2><p>The company also recently announced a special dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be paid a dividend of $0.31 per share. The ex-dividend date is Friday, May 15th. </p><h2>Institutional Investors Weigh In On Dominari</h2><p>A number of institutional investors and hedge funds have recently bought and sold shares of DOMH. Geode Capital Management LLC lifted its position in  Dominari by 2.9% in the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company's stock valued at $361,000 after acquiring an additional 1,866 shares during the last quarter.  Jane Street Group LLC purchased a new stake in shares of  Dominari in the second quarter valued at about $158,000.  Vanguard Group Inc. raised its holdings in shares of  Dominari by 8.0% in the third quarter. Vanguard Group Inc. now owns 345,896 shares of the company's stock valued at $2,452,000 after buying an additional 25,694 shares during the last quarter.  Two Sigma Investments LP purchased a new stake in shares of  Dominari in the third quarter valued at about $771,000.  Finally, Millennium Management LLC purchased a new stake in shares of  Dominari in the third quarter valued at about $213,000. 42.48% of the stock is owned by hedge funds and other institutional investors. </p><h2>Analyst Upgrades and Downgrades</h2><p>DOMH has been the subject of a number of analyst reports. Weiss Ratings downgraded shares of Dominari from a &#34;hold (c-)&#34; rating to a &#34;sell (d+)&#34; rating in a research note on Monday, January 12th. Wall Street Zen downgraded shares of Dominari from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, April 18th. One research analyst  has rated the stock with a Sell rating,  According to MarketBeat, the company  has an average rating of &#34;Sell&#34;.</p><p><b>View Our Latest Report on Dominari</b></p><h2>About Dominari</h2> (Get Free Report)<p>Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.</p><h2>Read More</h2><ul><li>Five stocks we like better than Dominari</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE9NSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE9NSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Dominari Right Now?</h2><p>Before you consider Dominari, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.</p><p>While Dominari currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DOMH

LABU

SBIO

<p>Dominari (NASDAQ:DOMH) is set to release its quarterly earnings on May 13, with analysts predicting a loss of $0.17 per share and revenue of $30.08 million. The stock has seen a 7.6% increase, opening at $3.39. Dominari also announced a special dividend of $0.31 per share, payable on May 29. Institutional investors hold 42.48% of the stock, with recent activity from firms like Geode Capital and Vanguard. Analysts have downgraded the stock to a 'Sell' rating, reflecting a cautious outlook on its performance.</p>

Dominari (DOMH) Projected to Post Quarterly Earnings on Wednesday